Krystal Biotech (KRYS) Expected to Announce Earnings on Tuesday

Krystal Biotech (NASDAQ:KRYS) is expected to be releasing its Q4 2025 results before the market opens on Tuesday, February 17th. Analysts expect the company to announce earnings of $1.62 per share and revenue of $105.30 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, February 17, 2026 at 8:30 AM ET.

Krystal Biotech Stock Up 2.3%

KRYS stock opened at $276.45 on Friday. The company has a 50-day simple moving average of $262.06 and a 200 day simple moving average of $205.72. Krystal Biotech has a fifty-two week low of $122.80 and a fifty-two week high of $295.98. The company has a market capitalization of $8.02 billion, a P/E ratio of 41.45 and a beta of 0.49.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on KRYS. TD Cowen reaffirmed a “buy” rating on shares of Krystal Biotech in a research report on Friday, January 9th. The Goldman Sachs Group upped their target price on shares of Krystal Biotech from $206.00 to $327.00 and gave the stock a “buy” rating in a report on Friday, January 30th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Krystal Biotech in a research report on Monday, December 29th. Bank of America lifted their price objective on Krystal Biotech from $288.00 to $318.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. Finally, Chardan Capital upped their price objective on Krystal Biotech from $216.00 to $220.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Nine research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $277.89.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $220.16, for a total transaction of $5,504,000.00. Following the transaction, the insider directly owned 1,413,711 shares of the company’s stock, valued at $311,242,613.76. This trade represents a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Kathryn Romano sold 12,500 shares of the business’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $272.14, for a total transaction of $3,401,750.00. Following the sale, the chief accounting officer directly owned 19,318 shares in the company, valued at $5,257,200.52. The trade was a 39.29% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 13.70% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in KRYS. Royal Bank of Canada raised its stake in shares of Krystal Biotech by 145.2% during the 1st quarter. Royal Bank of Canada now owns 1,628 shares of the company’s stock worth $294,000 after buying an additional 964 shares during the period. AQR Capital Management LLC increased its holdings in shares of Krystal Biotech by 29.9% in the first quarter. AQR Capital Management LLC now owns 12,131 shares of the company’s stock valued at $2,187,000 after purchasing an additional 2,792 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Krystal Biotech by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company’s stock valued at $2,870,000 after buying an additional 688 shares in the last quarter. Empowered Funds LLC acquired a new stake in shares of Krystal Biotech in the 1st quarter worth approximately $218,000. Finally, Cetera Investment Advisers grew its holdings in Krystal Biotech by 107.9% during the 2nd quarter. Cetera Investment Advisers now owns 4,344 shares of the company’s stock valued at $597,000 after buying an additional 2,255 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.